Creatinine Clearance Calculator (CrCl, Cockcroft-Gault)
Input
Creatinine Clearance
—
About
The Cockcroft-Gault equation estimates creatinine clearance (CrCl) from serum creatinine, age, body weight, and sex. It estimates CrCl — not GFR — and, unlike eGFR, is not normalized to body surface area and includes body weight directly. Use in: estimating kidney function for medication dose adjustment. Many drug labels still express their renal dose-adjustment thresholds in terms of Cockcroft-Gault CrCl rather than eGFR, which is the main reason this older index is still calculated even though guidelines now favor eGFR for assessing kidney function. Not recommended for: general kidney-function assessment or CKD staging. The National Kidney Foundation states the Cockcroft-Gault formula has not been expressed using standardized creatinine values and is no longer recommended for clinical use; the NKF 2025 race-free consensus and the FDA's 2024 renal-impairment guidance both recommend moving toward the race-free CKD-EPI eGFR. The practical tension that keeps Cockcroft-Gault in use: hospital labs now report only eGFR, while many drug labels still specify CrCl. Least accurate in: the elderly, obesity, very low or high muscle mass (cachexia, amputees, paralysis), and unstable (non–steady-state) creatinine such as acute kidney injury, where the equation's assumptions break down.
Formula
Interpretation
| CrCl (mL/min) | Kidney Function |
|---|---|
| ≥ 90 | Normal |
| 60 – 89 | Mild decrease |
| 30 – 59 | Moderate decrease |
| 15 – 29 | Severe decrease |
| < 15 | Kidney failure |
References
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
- National Kidney Foundation. Cockcroft-Gault Formula — not expressed using standardized creatinine values; not recommended for clinical use.
- NKF Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions. Consensus recommendations to transition from Cockcroft-Gault to race-free CKD-EPI eGFR. Am J Health-Syst Pharm. 2025;82(12):644-661.
- U.S. Food and Drug Administration. Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing. Guidance for Industry (final, 2024).
FAQ
Disclaimer
For educational and informational purposes only. Not intended to replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.